{
    "abstract": "The blood-brain barrier (BBB) severely limits the delivery of therapeutic agents to the brain. Regadenoson, a Food and Drug Administration-approved adenosine A2 agonist, transiently increases BBB permeability in rodents to a 70\u00a0kDa dextran. This multi-institutional, NIH-funded study examined regadenoson's ability to transiently alter BBB permeability in patients with gliomas.\nAdults with supratentorial gliomas at low risk for regadenoson complications were treated with 1 of the 7 dose levels known to be safe in humans. Successful BBB disruption was defined as a 10-fold increase in vascular permeability (\nSeven patients <45 years old with low-grade gliomas were accrued before the study was prematurely closed. Regadenoson was well tolerated. Following regadenoson, \nNo dose of regadenoson significantly elevated \nNCI Protocol #: Adult brain tumor consortium 1804, ClinicalTrials.gov Identifier: ",
    "authors": [
        {
            "affiliation": "Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.",
            "firstname": "Stuart A",
            "initials": "SA",
            "lastname": "Grossman"
        },
        {
            "affiliation": "Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.",
            "firstname": "Carlos G",
            "initials": "CG",
            "lastname": "Romo"
        },
        {
            "affiliation": "Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.",
            "firstname": "Xiaobu",
            "initials": "X",
            "lastname": "Ye"
        },
        {
            "affiliation": "Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.",
            "firstname": "Brian",
            "initials": "B",
            "lastname": "Kral"
        },
        {
            "affiliation": "Department of Internal Medicine, Hematology and Oncology, Wake Forest University School of Medicine, Wake Forest, North Carolina, USA.",
            "firstname": "Roy E",
            "initials": "RE",
            "lastname": "Strowd"
        },
        {
            "affiliation": "Department of Internal Medicine, Hematology and Oncology, Wake Forest University School of Medicine, Wake Forest, North Carolina, USA.",
            "firstname": "Glenn",
            "initials": "G",
            "lastname": "Lesser"
        },
        {
            "affiliation": "UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, Center for Computer Vision and Imaging Biomarkers, Los Angeles, California, USA.",
            "firstname": "Catalina",
            "initials": "C",
            "lastname": "Raymond"
        },
        {
            "affiliation": "Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.",
            "firstname": "Michaella",
            "initials": "M",
            "lastname": "Iacoboni"
        },
        {
            "affiliation": "Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.",
            "firstname": "Serena",
            "initials": "S",
            "lastname": "Desideri"
        },
        {
            "affiliation": "Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.",
            "firstname": "Joy",
            "initials": "J",
            "lastname": "Fisher"
        },
        {
            "affiliation": "Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.",
            "firstname": "Neeraja",
            "initials": "N",
            "lastname": "Danda"
        },
        {
            "affiliation": "UCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, Center for Computer Vision and Imaging Biomarkers, Los Angeles, California, USA.",
            "firstname": "Benjamin M",
            "initials": "BM",
            "lastname": "Ellingson"
        }
    ],
    "conclusions": null,
    "copyrights": "\u00a9 The Author(s) 2025. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.",
    "doi": "10.1093/noajnl/vdaf041",
    "journal": "Neuro-oncology advances",
    "keywords": [
        "adenosine agonist",
        "blood-brain barrier",
        "gadolinium",
        "glioma",
        "magnetic resonance imaging (MRI)"
    ],
    "methods": null,
    "publication_date": "2025-04-14",
    "pubmed_id": "40225909\n29117289\n18669428\n34829989\n35100958\n15717053\n31707548\n24048799\n38578405\n9932880\n12637469\n32076934\n27854097\n12754091\n8856161\n16408203\n21917810\n26330053\n25262373\n27043281\n18600537\n26626489\n28315063\n29332604\n17112296\n26607361\n16325044\n10508281\n2062210\n15503330\n27185374\n29474640\n24475840\n10815665\n27580889\n22581762\n22381582\n23673143\n29660005\n24120142\n23917401\n27414067\n31541850\n15173079\n29572621\n25074746\n26077645\n39449749\n34988454",
    "results": "Seven patients <45 years old with low-grade gliomas were accrued before the study was prematurely closed. Regadenoson was well tolerated. Following regadenoson, ",
    "title": "Assessing the dose of regadenoson required to transiently alter blood-brain barrier integrity in patients with infiltrating gliomas.",
    "xml": "<Element 'PubmedArticle' at 0x7885049622f0>"
}